Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study
Daniela Paola Roggeri,1 Mario Cozzolino,2 Sandro Mazzaferro,3 Diego Brancaccio,4 Ernesto Paoletti,5 Alessandro Roggeri,1 Anna Maria Costanzo,6 Umberto di Luzio Paparatti,6 Vincenzo Festa,6 Piergiorgio Messa7 1ProCure Solutions, Nembro, Bergamo, 2Department of Health Sciences, University of Milan, M...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-12-01
|
Series: | International Journal of Nephrology and Renovascular Disease |
Online Access: | http://www.dovepress.com/evaluating-targets-and-costs-of-treatment-for-secondary-hyperparathyro-peer-reviewed-article-IJNRD |
id |
doaj-34ced0edcebb4f5e844d4fa76086e05d |
---|---|
record_format |
Article |
spelling |
doaj-34ced0edcebb4f5e844d4fa76086e05d2020-11-24T22:51:56ZengDove Medical PressInternational Journal of Nephrology and Renovascular Disease1178-70582014-12-012015default1619614Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 studyRoggeri DPCozzolino MMazzaferro SBrancaccio DPaoletti ERoggeri ACostanzo AMdi Luzio Paparatti UFesta VMessa P Daniela Paola Roggeri,1 Mario Cozzolino,2 Sandro Mazzaferro,3 Diego Brancaccio,4 Ernesto Paoletti,5 Alessandro Roggeri,1 Anna Maria Costanzo,6 Umberto di Luzio Paparatti,6 Vincenzo Festa,6 Piergiorgio Messa7 1ProCure Solutions, Nembro, Bergamo, 2Department of Health Sciences, University of Milan, Milan, 3Department of Cardiovascular, Respiratory, Nephrologic and Geriatric Sciences, Sapienza University of Rome, Rome, 4Dialysis Unit NephroCare Simone Martini, Milan, 5Department of Nephrology, San Martino Hospital, Genoa, 6AbbVie Italy, Campoverde, Latina, 7Nephrology, Dialysis and Renal Transplant, Fondazione Ca Granda IRCCS Policlinico, Milan, Italy On behalf of the FARO Study Group Background: The aim of this analysis was to estimate biochemical parameters and the costs of treatment of secondary hyperparathyroidism (SHPT) in a subpopulation of the FARO-2 study. Methods: The FARO-2 observational study aimed at evaluating the patterns of treatment for SHPT in naïve hemodialysis patients. Data related to pharmacological treatments and biochemical parameters (parathyroid hormone [PTH], calcium, phosphate) were recorded at entry to hemodialysis (baseline) and 6 months later (second survey). The analysis was performed from the Italian National Health Service perspective. Results: Two prominent treatment groups were identified, ie, one on oral calcitriol (n=105) and the other on intravenous paricalcitol (n=33); the intravenous calcitriol and intravenous paricalcitol + cinacalcet combination groups were not analyzed due to low patient numbers. At baseline, serum PTH levels were significantly higher in the intravenous paricalcitol group (P<0.0001). At the second survey, the intravenous paricalcitol group showed a higher percentage of patients at target for PTH than in the oral calcitriol group without changing the percentage of patients at target for phosphate. Moreover, between baseline and the second survey, intravenous paricalcitol significantly increased both the percentage of patients at target for PTH (P=0.033) and the percentage of patients at target for the combined endpoint PTH, calcium, and phosphate (P=0.001). The per-patient weekly pharmaceutical costs related to SHPT treatment, erythropoietin-stimulating agents and phosphate binders accounted for 186.32€ and 219.94€ at baseline for oral calcitriol and intravenous paricalcitol, respectively, while after 6 months, the costs were 180.51€ and 198.79€, respectively. Either at the beginning of dialysis or 6 months later, the total cost of SHPT treatment was not significantly lower in the oral calcitriol group compared with the intravenous paricalcitol group, with a difference among groups that decreased by 46% between the two observations. The cost of erythropoietin stimulating agents at the second survey was lower (−22%) in the intravenous paricalcitol group than in the oral calcitriol group (132.13€ versus 168.36€, respectively). Conclusion: Intravenous paricalcitol significantly increased the percentage of patients at target for the combined endpoint of PTH, calcium, and phosphate (P=0.001). The total cost of treatment for the patients treated with intravenous paricalcitol 6 months after entry to dialysis was not significantly higher than the cost for patients treated with oral calcitriol. Keywords: cost consequences analysis, therapeutic costs, outcomes, SHPT treatments, secondary hyperparathyroidismhttp://www.dovepress.com/evaluating-targets-and-costs-of-treatment-for-secondary-hyperparathyro-peer-reviewed-article-IJNRD |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Roggeri DP Cozzolino M Mazzaferro S Brancaccio D Paoletti E Roggeri A Costanzo AM di Luzio Paparatti U Festa V Messa P |
spellingShingle |
Roggeri DP Cozzolino M Mazzaferro S Brancaccio D Paoletti E Roggeri A Costanzo AM di Luzio Paparatti U Festa V Messa P Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study International Journal of Nephrology and Renovascular Disease |
author_facet |
Roggeri DP Cozzolino M Mazzaferro S Brancaccio D Paoletti E Roggeri A Costanzo AM di Luzio Paparatti U Festa V Messa P |
author_sort |
Roggeri DP |
title |
Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study |
title_short |
Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study |
title_full |
Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study |
title_fullStr |
Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study |
title_full_unstemmed |
Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study |
title_sort |
evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the faro-2 study |
publisher |
Dove Medical Press |
series |
International Journal of Nephrology and Renovascular Disease |
issn |
1178-7058 |
publishDate |
2014-12-01 |
description |
Daniela Paola Roggeri,1 Mario Cozzolino,2 Sandro Mazzaferro,3 Diego Brancaccio,4 Ernesto Paoletti,5 Alessandro Roggeri,1 Anna Maria Costanzo,6 Umberto di Luzio Paparatti,6 Vincenzo Festa,6 Piergiorgio Messa7 1ProCure Solutions, Nembro, Bergamo, 2Department of Health Sciences, University of Milan, Milan, 3Department of Cardiovascular, Respiratory, Nephrologic and Geriatric Sciences, Sapienza University of Rome, Rome, 4Dialysis Unit NephroCare Simone Martini, Milan, 5Department of Nephrology, San Martino Hospital, Genoa, 6AbbVie Italy, Campoverde, Latina, 7Nephrology, Dialysis and Renal Transplant, Fondazione Ca Granda IRCCS Policlinico, Milan, Italy On behalf of the FARO Study Group Background: The aim of this analysis was to estimate biochemical parameters and the costs of treatment of secondary hyperparathyroidism (SHPT) in a subpopulation of the FARO-2 study. Methods: The FARO-2 observational study aimed at evaluating the patterns of treatment for SHPT in naïve hemodialysis patients. Data related to pharmacological treatments and biochemical parameters (parathyroid hormone [PTH], calcium, phosphate) were recorded at entry to hemodialysis (baseline) and 6 months later (second survey). The analysis was performed from the Italian National Health Service perspective. Results: Two prominent treatment groups were identified, ie, one on oral calcitriol (n=105) and the other on intravenous paricalcitol (n=33); the intravenous calcitriol and intravenous paricalcitol + cinacalcet combination groups were not analyzed due to low patient numbers. At baseline, serum PTH levels were significantly higher in the intravenous paricalcitol group (P<0.0001). At the second survey, the intravenous paricalcitol group showed a higher percentage of patients at target for PTH than in the oral calcitriol group without changing the percentage of patients at target for phosphate. Moreover, between baseline and the second survey, intravenous paricalcitol significantly increased both the percentage of patients at target for PTH (P=0.033) and the percentage of patients at target for the combined endpoint PTH, calcium, and phosphate (P=0.001). The per-patient weekly pharmaceutical costs related to SHPT treatment, erythropoietin-stimulating agents and phosphate binders accounted for 186.32€ and 219.94€ at baseline for oral calcitriol and intravenous paricalcitol, respectively, while after 6 months, the costs were 180.51€ and 198.79€, respectively. Either at the beginning of dialysis or 6 months later, the total cost of SHPT treatment was not significantly lower in the oral calcitriol group compared with the intravenous paricalcitol group, with a difference among groups that decreased by 46% between the two observations. The cost of erythropoietin stimulating agents at the second survey was lower (−22%) in the intravenous paricalcitol group than in the oral calcitriol group (132.13€ versus 168.36€, respectively). Conclusion: Intravenous paricalcitol significantly increased the percentage of patients at target for the combined endpoint of PTH, calcium, and phosphate (P=0.001). The total cost of treatment for the patients treated with intravenous paricalcitol 6 months after entry to dialysis was not significantly higher than the cost for patients treated with oral calcitriol. Keywords: cost consequences analysis, therapeutic costs, outcomes, SHPT treatments, secondary hyperparathyroidism |
url |
http://www.dovepress.com/evaluating-targets-and-costs-of-treatment-for-secondary-hyperparathyro-peer-reviewed-article-IJNRD |
work_keys_str_mv |
AT roggeridp evaluatingtargetsandcostsoftreatmentforsecondaryhyperparathyroidisminincidentdialysispatientsthefaro2study AT cozzolinom evaluatingtargetsandcostsoftreatmentforsecondaryhyperparathyroidisminincidentdialysispatientsthefaro2study AT mazzaferros evaluatingtargetsandcostsoftreatmentforsecondaryhyperparathyroidisminincidentdialysispatientsthefaro2study AT brancacciod evaluatingtargetsandcostsoftreatmentforsecondaryhyperparathyroidisminincidentdialysispatientsthefaro2study AT paolettie evaluatingtargetsandcostsoftreatmentforsecondaryhyperparathyroidisminincidentdialysispatientsthefaro2study AT roggeria evaluatingtargetsandcostsoftreatmentforsecondaryhyperparathyroidisminincidentdialysispatientsthefaro2study AT costanzoam evaluatingtargetsandcostsoftreatmentforsecondaryhyperparathyroidisminincidentdialysispatientsthefaro2study AT diluziopaparattiu evaluatingtargetsandcostsoftreatmentforsecondaryhyperparathyroidisminincidentdialysispatientsthefaro2study AT festav evaluatingtargetsandcostsoftreatmentforsecondaryhyperparathyroidisminincidentdialysispatientsthefaro2study AT messap evaluatingtargetsandcostsoftreatmentforsecondaryhyperparathyroidisminincidentdialysispatientsthefaro2study |
_version_ |
1725667952931373056 |